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HeidelbergAbstractStaphylococcus aureus is emerging globally. Treatment of infections is complicated by increasing antibiotic resistance. We collected clinical data
and swabs of returnees with skin and soft tissue infections (SSTI) at 13 travel-clinics in Europe (www.staphtrav.eu). Sixty-two percent (196/
318) SSTI patients had S. aureus-positive lesions, of which almost two-thirds (122/196) were Panton–Valentine leukocidin (PVL) positive. PVL
was associated with disease severity, including hospitalization for SSTI (OR 5.2, 95% CI 1.5–18.2). In returnees with SSTI, longer travel and
more intense population contact were risk factors for nasal colonization with PVL-positive S. aureus. Imported S. aureus frequently proved
resistant to trimethoprim-sulfamethoxazole (21%), erythromycin (21%), tetracycline (20%), ciproﬂoxacin (13%), methicillin (12%) and
clindamycin (8%). Place of exposure was signiﬁcantly (p < 0.05) associated with predominant resistance phenotypes and spa genotypes:
Latin America (methicillin; t008/CC24/304), Africa (tetracycline, trimethoprim-sulfamethoxazole; t084/CC84, t314/singleton, t355/
CC355), South Asia (trimethoprim-sulfamethoxazole, ciproﬂoxacin; t021/CC21/318), South-East Asia (clindamycin; t159/CC272).
USA300-like isolates accounted for 30% of all methicillin-resistant S. aureus imported to Europe and were predominantly (71%) acquired
in Latin America. Multi-resistance to non-β-lactams were present in 24% of imports and associated with travel to South Asia (ORcrude
5.3, 95% CI 2.4–11.8), even after adjusting for confounding by genotype (ORadjusted 3.8, 95% 1.5–9.5). Choosing randomly from
compounds recommended for the empiric treatment of severe S. aureus SSTI, 15% of cases would have received ineffective antimicrobial
therapy. These ﬁndings call for the development of regionally stratiﬁed guidance on the antibiotic management of severe imported
S. aureus disease and put the infected and colonized traveller at the centre of interventions against the global spread of multi-resistant
S. aureus.
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E-mail: philipp.zanger@uni-heidelberg.deIntroductionSkin abscesses account for about 1% of all post-travel consul-
tations [1] with Staphylococcus aureus being by far their most
common cause [2,3]. Incision and drainage is the therapy of
choice, but complicated skin and soft tissue infection (SSTI)
characterized by deep tissue involvement, extensive inﬂamma-
tion, recurrence and household clustering has become an
increasingly recognized entity in travel medicine [4–6]. In these
cases, the empiric choice of antibiotic compound can be a true
challenge because the prevalence of resistance to both, meth-
icillin and oral non-β-lactams in imported S. aureus is largely
unknown. Accordingly, existing recommendations for the
treatment of severe SSTI cannot provide guidance on the
empiric choice of antibiotic for returning travellers [7–9]
although the increased incidence and virulence of S. aureus
SSTI in this population clearly indicate a need.
Here, we (i) describe the clinical and microbiological char-
acteristics and risk factors of SSTI among intercontinental
travellers consulting a sentinel network of European travel
clinics; (ii) characterize imported S. aureus with respect to
resistance phenotype, genotype and virulence genes; and (iii)
analyse mutual associations between clinical presentation, strain
characteristics and geographic exposure. With our results, we
aim to inform (i) treatment decisions for travel-associated SSTI,
(ii) the content of pre-travel counselling and (iii) population
level measures against the global spread of virulent and
antibiotic-resistant staphylococci.Materials and methodsPatients with travel-associated SSTI have been prospectively
identiﬁed since 2011 in a sentinel surveillance network on im-
ported S. aureus comprising several participating travel clinics in
Europe (www.staphtrav.eu). Contributors anonymously submit
one lesion swab and one nasal swab from patients with travel-
associated SSTI to a centralized laboratory in Germany. For
inclusion, a patient has to (i) suffer from a skin infection on the
day of the clinic visit, (ii) have returned from a trip outsidenical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectEurope, and (iii) have experienced onset of SSTI while abroad
or within 30 days after the end of the journey. In addition, brief
demographic, travel and clinical characteristics of the patient
are documented. This report presents the analysis of specimens
and data collected from May 2011 to December 2013.
Bacterial culture
Swab materials delivered by mail or international courier ser-
vice were cultured on mannitol–salt agar, selective for staph-
ylococci, within 12 h after arrival at the study centre’s
laboratory. Colonies showing mannitol fermentation were sub-
cultivated on Columbia Agar with 5% sheep blood, tested for
bound and free coagulase, and conﬁrmed as S. aureus by
ampliﬁcation of the coa gene [10].
Antibiotic susceptibility testing
Antimicrobial susceptibility was determined by disc diffusion
according to the European Committee on Antimicrobial Sus-
ceptibility Testing. The antimicrobial agents tested were
cefoxitin, trimethoprim-sulfamethoxazole, clindamycin, eryth-
romycin, ciproﬂoxacin, tetracycline, gentamicin and rifampicin
(Becton Dickinson, Heidelberg, Germany). Inducible clindamy-
cin resistance was tested for all isolates resistant to erythro-
mycin and susceptible to clindamycin [11].
Resistance and virulence genes
All strains were tested for mecA and Panton–Valentine leuko-
cidin (PVL) (lukS/lukF) by PCR [12]. The SCCmec types I–V of all
methicillin-resistant S. aureus (MRSA) were determined by PCR
[13]. MRSA isolates of spa type t008 were tested for the argi-
nine catabolic mobile element ACME-arcA [14].
Spa typing and multi locus sequencing
All S. aureus isolates were characterized by spa genotyping
(http://www.spaserver.ridom.de) [15]. Spa types were clus-
tered into spa clonal complexes (spa-CC) using the Based Upon
Repeat Pattern (BURP) algorithm with parameters set to
exclude if repeats were <5 and to cluster if cost 4 [16].
Analysis
Data were entered in two independent databases and checked
for inconsistencies using EPIDATA 3.1. If co-travellers were
affected by SSTI, only the index case was included. Multi-
resistance was deﬁned as: (i) resistance to any two or more
antibiotics and (ii) resistance to any two or more non-β-lactam
antibiotics tested for this study. The latter deﬁnition was cho-
sen to calculate estimates of multi-resistance to empirical
therapy when assuming MRSA infection a priori. For this study,
USA300 was deﬁned as arcA-positive, PVL-positive (PVL+),
SCCmec IVa-positive S. aureus of spa t008 [17]; PVL+, arcA-ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 567.e1–567.e10
CMI Nurjadi et al. Travel and import of S. aureus 567.e3negative, SCCmec IVc carrying isolates of spa t008 were
considered Latin American Variants [18]. Univariable and
multivariable logistic regression analyses were used to calculate
odds ratios, 95% conﬁdence intervals, and p-values for the
analysis of clinical and microbiological characteristics. All sta-
tistical procedures were performed using Stata 12.
Ethics
The study was approved by the Ethics Committee, Faculty of
Medicine, Eberhard Karls Universität, Tübingen and by the insti-
tutional review boards of the contributing centres, if necessary.
ResultsThirteen centres (Amsterdam, Barcelona, Basel, Berlin,
Hamburg, Helsinki, Munich, Paris, Rotterdam, Tübingen (two),
Vienna and Würzburg) submitted 351 lesional swabs. Thirty-
three submissions were excluded because of protocol
violations (travel inside Europe, n = 7; onset of SSTI >30 days
after return, n = 8; non-travelling secondary cases, n = 5) or
clustering (SSTI in co-travellers, n = 13), leaving 318 indepen-
dent cases for the main analysis (Table 1).
Of these 318 submissions, 196 (62%) were positive for
S. aureus, 122 of 196 staphylococci contained PVL encoding
genes, 23 of 196 staphylococci were MRSA, and 22 of 23 MRSA
were PVL+. Cases had a median age of 31 years (interquartile
range 24 to 48 years) and were predominantly male (59%).
Predominating travel destinations were Africa (n = 102) and
South-East Asia (n = 92). Median travel duration was 28 days
(interquartile range 17–91 days). Primary purpose of travel was
leisure (60%), followed by voluntary aid work (21%); visiting
friends and relatives (10%); business (5%); and education (4%).
Ninety-nine (31%) of 318 cases with complete information
reported recurrent disease, 85 of 317 (27%) surgical drainage,
50 of 316 (16%) SSTI in close contacts, 257 of 317 (81%) use of
antibiotics for the treatment of SSTI, and 39 of 313 (12%)
hospitalization due to travel-associated SSTI (Table 1).
Of 196 imported S. aureus, ﬁve were not spa typeable; one
spa type was not performed. The remaining 190 isolates
belonged to 96 spa types and 16 spa clonal complexes: CC24/
304, n = 24; CC21/318, n = 24; CC2, n = 16; CC84, n = 13;
CC355, n = 13; CC272, n = 12; CC127, n = 12; CC345, n = 7;
CC34, n = 5; CC15, n = 3; CC131, n = 3; ﬁve clusters with no
founder, n = 11. Forty-two strains (27% of all spa types) were
singletons and ﬁve isolates were excluded for short repeats.
The genotypic characteristics of imported S. aureus by
methicillin-resistance, PVL status and travel destination are
summarized in the Supporting information (Fig. S1) and
Tables 2 and 3.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfStaphylococcus aureus-positive SSTIAmong all patients with travel-associated SSTI (Table 1, left
column), returnees with S. aureus-positive lesions tended to be
younger than patients with non-staphylococcal SSTI; also they
were somewhat less likely to have visited South Asia, and were
more often humanitarian mission travellers or visiting friends
and relatives. Clinically, S. aureus-positive lesions were found to
be more likely to present as deep lesions that require surgical
drainage and to cause recurrent disease, but less likely to
present as ulcers, and to be preceded by insect bites or other
minor trauma. The proportion of S. aureus-positive lesions
among all lesions did not differ with sex, travel duration, anti-
biotic treatment, inpatient treatment, anatomic location of
lesion or report of contact persons being ill with SSTI.
PVL-positive SSTI
Among S. aureus-positive SSTI, PVL was more often observed in
isolates imported from Africa and Latin America and less often
in those from the Paciﬁc region and South-East Asia (Table 1,
central column). The PVL+, compared with PVL-negative
(PVL–), S. aureus was strongly associated with abscess forma-
tion, recurrent disease, surgical drainage and lesions above the
waistline. Patients with PVL+ lesions were more likely to
require inpatient treatment when compared with travellers
with SSTI caused by PVL– S. aureus.
MRSA SSTI
Methicillin-resistant S. aureus accounted for 7% (23/318) of all
travel-associated SSTI and for 12% (23/196) of all S. aureus-pos-
itive cases. Travel to Latin America and for humanitarian pur-
poses or visiting friends and relatives were independent risk
factors for acquisition of MRSA (crude ORs, Table 1, right col-
umn; mutually adjusted ORs from multivariable model are, for
Latin America, 5.47, 95% CI 2.09–24.33, p 0.001 and, for visiting
friends and relatives, 2.84, 95%CI 1.13–7.15, p 0.03). Compared
with travellers with methicillin-susceptible S. aureus (MSSA),
cases with MRSA-related SSTI were more likely to report skin
infections in contact persons (Table 1, right column).
Seven of 23 independent MRSA imports (30%) were PVL+ and
spa type t008: four of the seven were SCCmec type IVa, arcA-
positive and three of the seven were SCCmec IVc, arcA-negative,
consistent with the USA300-0114 and USA300-Latin American
Variant lineages, respectively [18]. Five (71%) of these seven
potential USA300 were imported from Latin America (Table 3).
Other community-associated MRSA imported from the
Philippines and India revealed spa genotypes that are known to
be associated with the South-West Paciﬁc (spa t019) [19] and
the Bay of Bengal (spa t657) [20] clones (Table 3).ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 567.e1–567.e10
TABLE 1. Characteristics of returning travellers with skin and soft tissue infections
Characteristic
All skin and soft tissue infections, n [ 318 Staphylococcus aureus-positive skin and soft tissue infections, n [ 196
S. aureus other
OR (95% CI) p
PVL+ PVL−
OR (95% CI) p
MRSA MSSA
OR (95% CI) p(n [ 196) (%) (n [ 122) (%) (n [ 122) (%) (n [ 74) (%) (n [ 23) (%) (n [ 173) (%)
Female 77 (39) 52 (43) 0.9 (0.5-1.4) 0.6 51 (42) 26 (35) 1.3 (0.7–2.4) 0.4 11 (48) 66 (38) 1.5 (0.6–3.6) 0.4
Age in years (range)a 31 (23–45) 35.5 (25–51) 0.9 (0.8–1.0) 0.07 31 (23–46) 30 (24–44) 1.0 (0.9–1.2) 0.7 28 (22–39) 31 (24–45) 0.8 (0.6–1.1) 0.1
Travel characteristics
Destinationb
Latin America 32 (16) 15 (12) 1.4 (0.7–2.7) 0.3 25 (21) 7 (10) 2.5 (1.0–6.0) 0.05 10 (44) 22 (13) 5.3 (2.1–13.5) 0.001
Africa 64 (33) 38 (31) 1.1 (0.7–1.7) 0.8 47 (39) 17 (23) 2.1 (1.1–4.0) 0.03 3 (13) 61 (35) 0.3 (0.1–1.0) 0.04
South Asia 32 (16) 29 (24) 0.6 (0.4–1.1) 0.1 20 (16) 12 (16) 1.0 (0.5–2.2) 1.0 2 (9) 30 (17) 0.5 (0.1–2.0) 0.3
South-East Asia 57 (29) 35 (29) 1.0 (0.6–1.7) 0.9 27 (22) 30 (41) 0.4 (0.2–0.8) 0.007 8 (35) 49 (28) 1.3 (0.5–3.4) 0.5
Australia/Paciﬁc 8 (4) 3 (2) 1.7 (0.4–6.5) 0.5 2 (2) 6 (8) 0.2 (0.04–1.0) 0.05 0 (0) 8 (5) – 0.3c
Duration in daysd 28 (17–109) 30 (17–90) 1.0 (0.99–1.02) 0.4 28.5 (17–116) 28 (19–88) 1.0 (0.99–1.01) 0.5 31 (20–194) 28 (17–100) 1.0 (0.99–1.01) 0.7
Purposee
Leisure 109 (56) 81 (66) 0.6 (0.4–1.0) 0.06 61 (50) 48 (65) 0.5 (0.3–1.0) 0.04 10 (43) 99 (57) 0.6 (0.2–1.4) 0.2
Business/education 17 (9) 12 (10) 0.9 (0.4–1.9) 0.7 13 (11) 4 (5) 2.1 (0.7–6.7) 0.2 0 (0) 17 (10) – 0.1c
Humanitarian/VFR 69 (35) 29 (24) 1.7 (1.0–2.9) 0.03 47 (39) 22 (30) 1.5 (0.8–2.7) 0.2 13 (57) 56 (32) 2.7 (1.1–6.6) 0.03
Clinical characteristicsf
Type of lesion
Ulcer 53 (27) 57 (47) 0.4 (0.3–0.7) <0.001 12 (10) 41 (56) 0.1 (0.0–0.2) <0.001 2 (9) 51 (30) 0.2 (0.1–1.0) 0.05
Furuncle/abscess 132 (67) 56 (46) 2.4 (1.5–3.9) <0.001 105 (86) 27 (36) 10.8 (5.4–21.6) <0.001 19 (83) 113 (65) 2.5 (0.8–7.8) 0.1
Other 10 (5) 9 (7) 0.7 (0.3–1.7) 0.4 5 (4) 5 (7) 0.6 (0.2–2.1) 0.4 2 (9) 8 (5) 2.0 (0.4–9.9) 0.4
Deep lesion 85 (43) 40 (33) 1.6 (1.0–2.5) 0.07 71 (58) 14 (19) 6.0 (3.0–11.8) <0.001 11 (48) 74 (43) 1.2 (0.5–2.9) 0.6
Preceding trauma
None 109 (56) 48 (40) 1.9 (1.2–3.1) 0.006 79 (66) 30 (41) 2.8 (1.5–5.0) 0.001 14 (61) 95 (56) 1.2 (0.5–3.0) 0.7
Insect bites 62 (32) 50 (42) 0.7 (0.4–1.0) 0.08 35 (29) 27 (37) 0.7 (0.4–1.3) 0.3 6 (26) 56 (33) 0.7 (0.3–1.9) 0.5
Other 22 (11) 21 (18) 0.8 (0.6–1.1) 0.1 6 (5) 16 (22) 0.4 (0.3–0.7) 0.001 3 (13) 19 (11) 1.1 (0.6–2.1) 0.8
Recurrent episodes 70 (36) 29 (24) 1.8 (1.1–3.0) 0.03 55 (45) 15 (20) 3.2 (1.7–6.3) 0.001 13 (57) 57 (33) 2.6 (1.1–6.4) 0.03
Surgical drainage 66 (34) 19 (16) 2.7 (1.5–4.8) 0.001 61 (50) 5 (7) 13.8 (5.2–36.6) <0.001 12 (52) 54 (31) 2.4 (1.0–5.8) 0.05
Antibiotics prescribed 155 (79) 102 (84) 0.8 (0.4–1.4) 0.4 100 (83) 55 (74) 1.6 (0.8–3.3) 0.2 19 (83) 136 (79) 1.3 (0.4–3.9) 0.7
Contacts affected 34 (18) 16 (13) 1.4 (0.7–2.7) 0.3 22 (18) 12 (16) 1.2 (0.5–2.5) 0.7 8 (33) 27 (16) 2.5 (0.9–6.7) 0.07
Hospitalization due to
travel-associated SSTI
25 (13) 14 (12) 1.1 (0.6–2.3) 0.7 22 (18) 3 (4) 5.2 (1.5–18.2) 0.009 5 (22) 20 (12) 2.1 (0.7–6.2) 0.2
Location of lesiong
Below waistline 129 (70) 83 (74) 1 69 (60) 60 (87) 1 10 (50) 119 (73) 1
Above waistline 55 (30) 29 (26) 1.2 (0.7–2.1) 0.5 46 (40) 9 (13) 4.4 (2.0–9.8) <0.001 10 (50) 45 (27) 2.6 (1.0–6.8) 0.04
Data are number of subjects/bacterial isolates (column %) with given characteristic together with odds ratios (OR) and 95% conﬁdence intervals (95% CI) from univariable logistic regression. p values are testing H0: the odds of a given characteristic
are equal in the two comparison groups. p  0.05 shown in bold type.
Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; PVL, Panton–Valentine leukocidin; VFR, visiting friends and relatives.
aMedian (inter quartile range); odds ratios per 10 years increase in age.
bRow category of cases with other destinations (Turkey, Mongolia, Afghanistan, Azerbaijan, USA) not displayed.
cFrom χ2-test.
dMedian (interquartile range); odds ratios per 14 days increase in duration of travel; information on travel duration of four subjects missing.
eRow category of one case patient with ‘other’ purpose not displayed.
fMissing data among skin and soft tissue infections (SSTI) overall (left column): presentation (n = 1), depth of lesion (n = 1), trauma (n = 6), contacts affected (n = 2), surgical drainage (n = 1), antibiotics (n = 1), hospitalization (n = 5); missing data
among S. aureus-positive SSTI (central and right columns): presentation (n = 1), trauma (n = 3), contacts affected (n = 2), antibiotics (n = 1), hospitalization (n = 3).
gMissing data on anatomic location of lesion among SSTI overall (left column) (n = 22) and in S. aureus-positive SSTI (central and right columns) (n = 12).
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TABLE 2. Phenotypic and genotypic characteristics of imported Staphylococcus aureus by place of exposure
Characteristica
Travel to Total
(n [ 196)
Latin Americac, (n [ 32) Africad, (n [ 64) South Asiae, (n [ 32) South-East Asiaf, (n [ 57) Australia/Paciﬁcg, (n [ 8)
n (%) OR (CI) n (%) OR (CI) n (%) OR (CI) n (%) OR (CI) n (%) OR (CI) n (%)
Resistanceb
SXT 4 (12.5) 0.5 (0.2–1.5) 19 (29.7) 2.1 (1.0–4.3) 14 (43.8) 3.9 (1.8–8.9) 4 (7.0) 0.2 (0.1–0.6) 0 (0.0) n/a 41 (20.9)
Erythromycin 9 (28.1) 1.6 (0.7–3.8) 1 (1.6) 0.04 (0.0–0.3) 16 (50.0) 5.6 (2.5–12.5) 13 (22.8) 1.2 (0.6–2.5) 2 (25.0) 1.3 (0.2–6.6) 41 (20.9)
Tetracycline 4 (12.5) 0.5 (0.2–1.5) 22 (34.4) 3.3 (1.6–6.8) 2 (6.3) 0.2 (0.1–1.0) 11 (19.3) 0.9 (0.4–2.0) 1 (12.5) 0.6 (0.1–4.6) 40 (20.4)
Ciproﬂoxacin 3 (9.4) 0.6 (0.2–2.3) 2 (3.1) 0.1 (0.0–0.6) 17 (53.1) 19.5 (7.4–51.3) 3 (5.3) 0.3 (0.1–1.0) 1 (12.5) 0.9 (0.1–7.9) 26 (13.3)
Methicillin (MRSA) 10 (31.3) 5.3 (2.1–13.5) 3 (4.7) 0.3 (0.1–1.0) 2 (6.3) 0.5 (0.1–2.0) 8 (14.0) 1.3 (0.5–3.4) 0 (0.0) n/a 23 (11.7)
Clindamycin 2 (6.3) 0.8 (0.2–3.6) 0 (0.0) n/a 3 (9.4) 1.3 (0.3–4.9) 9 (15.8) 4.2 (1.4–12.3) 1 (12.5) 1.8 (0.2–15.5) 15h (7.7)
Empiric failure (%)i — (15.7) — — (17.2) — — (16.5) — — (14.0) — — (6.3) — — (15.2)
Genotype
CC21/318 3 (9.4) 0.7 (0.2–2.5) 6 (9.4) 0.7 (0.2–1.7) 12 (37.5) 7.6 (3.0–19.2) 3 (5.3) 0.3 (0.1–1.1) 0 (0.0) n/a 24 (12.2)
t021 0 (0.0) n/a 1 (1.6) 0.2 (0.0–1.5) 9 (28.1) 31.7 (6.4–155.9) 1 (1.8) 0.2 (0.0–1.8) 0 (0.0) n/a 11 (5.6)
CC24/304 10 (31.3) 4.9 (1.9–12.3) 5 (7.8) 0.5 (0.2–1.4) 2 (6.3) 0.4 (0.1–1.9) 5 (8.8) 0.6 (0.2–1.7) 2 (25.0) 2.5 (0.5–13.2) 24 (12.2)
t008 7 (21.9) 8.9 (2.6–30.2) 2 (3.1) 0.4 (0.1–1.9) 0 (0.0) n/a 2 (3.5) 0.5 (0.1–2.2) 1 (12.5) 2.3 (0.3–20.4) 12 (6.1)
CC2 3 (9.4) 1.2 (0.3–4.5) 4 (6.3) 0.7 (0.2–2.2) 2 (6.3) 0.7 (0.2–3.3) 5 (8.8) 1.1 (0.4–3.4) 2 (25.0) 4.1 (0.8–22.5) 16 (8.2)
t002 2 (6.3) 1.8 (0.3–9.1) 0 (0.0) n/a 2 (6.3) 1.8 (0.3.9.1) 2 (3.5) 0.8 (0.2–4.1) 2 (25.0) 10.1 (1.7–60.9) 8 (4.1)
CC84 0 (0.0) n/a 8 (12.5) 3.6 (1.1–11.6) 1 (3.1) 0.4 (0.1–3.3) 4 (7.0) 1.1 (0.2–4.1) 0 (0.0) n/a 13 (6.6)
t084 0 (0.0) n/a 7 (10.9) 8.0 (1.6–39.6) 0 (0.0) n/a 2 (3.5) 0.7 (0.1–3.4) 0 (0.0) n/a 9 (4.6)
CC355 2 (6.3) 0.9 (0.2–4.4) 10 (15.6) 8.0 (2.1–30.1) 0 (0.0) n/a 1 (1.8) 0.2 (0.0–1.5) 0 (0.0) n/a 13 (6.6)
t355 1 (3.1) 0.6 (0.1–4.5) 8 (12.5) 9.3 (1.9–45.1) 0 (0.0) n/a 1 (1.8) 0.3 (0.0–2.1) 0 (0.0) n/a 10 (5.1)
CC272 0 (0.0) n/a 5 (7.8) 1.5 (0.5–5.0) 1 (3.1) 0.4 (0.1–3.6) 6 (10.5) 2.6 (0.8–8.5) 0 (0.0) n/a 12 (6.1)
t159 0 (0.0) n/a 1 (1.6) 0.5 (0.1–4.6) 0 (0.0) n/a 4 (7.0) 10.4 (1.1–95.3) 0 (0.0) n/a 5 (2.6)
t314/singleton 0 (0.0) n/a 6 (9.4) 13.6 (1.6–115.1) 0 (0.0) n/a 1 (1.8) 0.4 (0.0–3.4) 0 (0.0) n/a 7 (3.6)
CC345 1 (3.1) 0.8 (0.1–7.3) 0 (0.0) n/a 4 (12.5) 7.7 (1.6–36.1) 1 (1.8) 0.4 (0.0–3.4) 1 (12.5) 4.3 (0.5–41.0) 7 (3.6)
CC34 3 9.4 8.4 (1.3–52.4) 0 (0.0) n/a 0 (0.0) n.a. 2 (3.5) 1.6 (0.3–10.1) 0 (0.0) n.a. 5 (2.6)
Data are number (column %) of isolates with given resistance phenotype, clonal complex, and most common spa-type within a given clonal complex. Odds ratios (OR) and 95% conﬁdence intervals (CI) were derived from univariable logistic
regression. Conﬁdence intervals excluding an OR of 1.0 are given in bold.
Abbreviations: CC, Spa clonal complex; MRSA, methicillin-resistant S. aureus; SXT, trimethoprim-sulfamethoxazole.
Spa types clustering in CC’s were: CC2 (t002, t311, t088), CC21/318 (t021, t019, t318), CC34 (t034, t571), CC84 (t084), CC272 (t159, t645); CC24/304 (t008, t024 t701), CC345 (t345), CC355 (t355). Only strata of genotypes containing ﬁve or
more isolates and showing a signiﬁcant geographic association are displayed.
aThe column category ‘other regions’ containing one isolate each from Afghanistan, Azerbaijan and the USA was omitted from this table.
bRows and columns showing frequencies of resistance to gentamicin (n = 5) imported from India (n = 2), Thailand, Zambia, Afghanistan and to rifampicin (n = 1) imported from Thailand were omitted from this table.
cCountries (number of isolates) included were Mexico (1), Nicaragua (1), Costa Rica (2), Panama (1), Cuba (1), Haiti (1), Bahamas (1), Dominican Republic (9), Jamaica (1), Columbia (3), Surinam (4), Ecuador (1), Peru (1), Brazil (3), Paraguay (2).
dCountries (number of isolates) included were Morocco (1), Tunisia (1), Sudan (1), Niger (1), Cape Verde (1) Senegal (1), Gambia (3), Guinea Bissau (1), Equatorial Guinea (1), Sierra Leone (2), Ghana (6), Togo (1), Benin (1), Nigeria (2), Cameroon
(5), Democratic Republic of Congo (1), Republic of Congo (2), Rwanda (1), Burundi (1), Kenya (10), Uganda (4), Tanzania (4), Mozambique (2), Madagascar (2), Zambia (3), Malawi (3), South Africa (1), Namibia (1).
eCountries (number of independent isolates) included were Pakistan (1), India (19), Sri Lanka (7), Nepal (5),
fCountries (number of independent isolates) included were Thailand (25), Laos (3), Vietnam (4), Cambodia (2), Indonesia (8), Malaysia (3), Singapore (2), Philippines (10).
gCountries (number of independent isolates) included were Australia (1), Papua New Guinea (4), New Zealand (1), Fiji (2).
hEight of these 15 isolates were resistant to erythromycin and had a positive D-test, consistent with inducible resistance to clindamycin.
iProbability of failure of empiric therapy assuming a random selection from currently recommended, orally bioavailable ﬁrst-line and second-line compounds for the treatment of S. aureus SSTI, i.e. isoxazolyl penicillins, trimethoprim-sulfa-
methoxazole, tetracyclines, or clindamycin.
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TABLE 3. Travel-associated import of methicillin-resistant Staphylococcus aureus to Europe
No. Travel clinic Sex Age Purpose Region Country
spa
PVL SCCmec Co-resistanceaType CC
1 Helsinki M 59 Leisure Latin America Colombia t008b 24/304 Pos. IVc CIP
2 Berlin F 6 VFR Colombia t008b 24/304 Pos. IVc ERY
3 Basel F 25 Aid work Colombia t13392 Singleton Pos. n/tc None
4 Amsterdam F 2 Leisure Suriname t008d 24/304 Pos. IVa SXT, ERY, CIP
5 Würzburg M 47 VFR Cuba t008d 24/304 Pos. IVa ERY, CIP
6 Berlin M 18 VFR Bahamas t008d 24/304 Pos. IVa ERY
7 ITM Tübingen M 36 VFR Costa Rica t148 No foundere Pos. IVa None
8 ITM Tübingen F 23 Aid work Costa Rica t10437 No foundere Pos. IVa None
9 Basel F 28 Leisure Jamaica t024 24/304 Pos. IVc SXT
10 Berlin M 27 Leisure Panama t2393 No founderf Pos. IVc None
11 ITM Tübingen F 24 Aid work Africa South Africa t3812 Excluded Pos. IVc None
12 PLK Tübingen M 49 Aid work South Sudan t008c 24/304 Pos. IVc TET
13 Paris M 29 Leisure Madagascar t186 No founderf Pos. IVa None
14 Vienna F 39 Leisure South Asia India t657 345 Pos. V ERY, CIP, GM
15 PLK Tübingen F 21 Aid work India t304 24/304 Pos. IVa SXT, CIP
16 Hamburg F 23 Aid work South-East Asia Thailand t202 Singleton Pos. IVa None
17 ITM Tübingen M 32 Leisure Thailand t1671 Singleton Pos. IVa ERY
18 ITM Tübingen M 31 Leisure Thailand t008e 24/304 Pos. IVa ERY
19 ITM Tübingen M 22 Aid work The Philippines t019 21 Pos. IVc None
20 Paris M 54 Leisure The Philippines t002 2 Pos. IVc CC, ERY, TET
21 PLK Tübingen F 31 VFR The Philippines t019 21 Pos. IVc None
22 Berlin F 46 Leisure The Philippines n/t — Neg. IVc SXT
23 PLK Tübingen M 19 Aid work Vietnam t202 Singleton Pos. IVa None
All isolates tested positive for mecA.
Abbreviations: CC, spa clonal complex; f, female; ITM, Institute of Tropical Medicine; m, male; n/t, not typeable; PLK, Paul-Lechler Hospital; PVL, Panton–Valentine leukocidin; VFR,
visiting friends and relatives.
aResistance to the following additional antibacterial drugs was tested; trimethoprim-sulfamethoxazole (SXT), clindamycin (CC), erythromycin (ERY), ciproﬂoxacin (CIP), gentamicin
(GM), tetracycline (TET), rifampicin (RA).
barcA-negative, consistent with USA300 Latin American Variant.
cBy PCR for SCCmec types I–V.
darcA-positive, consistent with USA300-0114 lineage.
e,fThese spa types belong to the same cluster with no founder.
567.e6 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMINasal carriage
Nasal swabs were available for 310 of the 318 cases analysed.
Of these, 39% (122/310) were nasal carriers of S. aureus, 17%
(53/310) of PVL+ S. aureus, and 6% (18/310) of MRSA. Table 4
summarizes risk factors of various types of S. aureus nasal
carriage and their association with clinical characteristics of
SSTI in travellers.
Antimicrobial (multi-)resistance
Nearly half of all imported S. aureus (89/196) were resistant to
at least one compound currently used for the empiric treat-
ment of SSTI (i.e. isoxazolyl-penicillins, trimethoprim-sulfa-
methoxazole, tetracycline, clindamycin), 49% (96/196) were
resistant to at least one non-β-lactam, and 54% (106/196) to at
least one of the compounds tested in this study. Frequency and
patterns of antimicrobial resistance in imported S. aureus varied
largely by place of exposure abroad (Table 2; see Supporting
information, Fig. S2).
Resistance to two, three, four or seven of the tested com-
pounds simultaneously was observed in 16% (32/196), 8% (15/
196), 3% (6/196) and 0.5% (1/196) of imported isolate(s),
respectively. Multi-resistance to two or more of any of the tested
antibiotics was associated with travel to South Asia, various clin-
ical characteristics of severe SSTI, PVL-positivity, methicillin-
resistance and the spa types t021 and t008 (Table 5, left column).
Multi-resistance to two, three, four or seven non-β-lactamClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectantibiotics simultaneously was found in 13% (26/196), 8% (16/
196), 1.5% (3/196) and 0.5% (1/196) of isolate(s) and was asso-
ciated with travel to South Asia, various clinical characteristics of
severe SSTI, PVL-positivity, and the spa types t355 and t021, but
not with concomitant methicillin resistance or spa type t008
(Table 5, central column). To assess whether clonality
confounded the effect of exposure in South Asia on multi-
resistance to non-β-lactams in S. aureus, we ﬁtted a multivari-
able logistic regression model adjusting for those spa types that
were associated with both multi-resistance and South Asia. After
adjusting for some positive confounding, exposure in South Asia
remained a strong and independent predictor of multi-resistance
to non-β-lactams in imported S. aureus (Table 5, right column).
Choosing randomly from antibiotic compounds recom-
mended for the empiric treatment of skin and soft-tissue in-
fections (i.e. isoxazolyl-penicillins, trimethoprim-
sulfamethoxazole, tetracycline, clindamycin) [7–9], there was
an overall 15% chance to treat any of the returnees included in
this study ineffectively (Table 2).DiscussionIn this European multi-centre study, we found that antimi-
crobial (multi-)resistance in imported S. aureus is common
and its geographic distribution is globally heterogeneous. Weious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 567.e1–567.e10
TABLE 4. Risk factors for Staphylococcus aureus, PVL-positive S. aureus, and MRSA nasal carriage in travellers with skin and soft tissue infections
Characteristic
S. aureus nasal carriage PVL-positive S. aureus nasal carriage MRSA nasal carriage
Yes No
OR (95% CI) p
Yes No
OR (95% CI) p
Yes No
OR (95% CI) pn [ 122 (%) n [ 188 (%) n [ 53 (%) n [ 257 (%) n [ 18 (%) n [ 292 (%)
Female 52 (43) 74 (39) 1.1 (0.7–1.8) 0.6 24 (45) 102 40 1.3 (0.7–2.3) 0.5 11 (61) 115 (39) 2.4 (0.9–6.4) 0.08
Age in yearsa 31 (23–45) 31 (24–49) 0.9 (0.8–1.1) 0.3 31 (23–49) 31 (24–47) 1.0 (0.9–1.2) 0.8 29.5 (21–46) 31 (24–48) 0.8 (0.6–1.1) 0.2
Travel characteristics
Destinationb
Latin America 17 (14) 30 (16) 0.9 (0.4–1.6) 0.6 9 (17) 38 15 1.2 (0.5–2.6) 0.7 6 (33) 41 (14) 3.1 (1.1–8.6) 0.03
Africa 43 (35) 58 (31) 1.2 (0.8–2.0) 0.4 20 (38) 81 32 1.3 (0.7–2.4) 0.4 1 (6) 100 (34) 0.1 (0.1–0.9) 0.04
South Asia 26 (21) 31 (16) 1.4 (0.8–2.4) 0.3 12 (23) 45 18 1.4 (0.7–2.8) 0.4 6 (33) 51 (17) 2.4 (0.8–6.6) 0.1
South-East Asia 33 (27) 56 (30) 0.9 (0.5–1.5) 0.6 11 (21) 78 30 0.6 (0.3–1.2) 0.2 5 (28) 84 (29) 1.0 (0.3–2.8) 0.9
Australia/Paciﬁc 2 (2) 9 (5) 0.3 (0.1–1.6) 0.2 1 (2) 10 4 0.5 (0.1–3.8) 0.5 0 (0) 11 (4) – 0.4c
Duration in daysd 31 (20–112) 28 (17–83) 1.01 (1.00–1.03) 0.2 63 (22–195) 28 (17–83) 1.02 (1.00–1.04) 0.02 38 (21–305) 28 (17–90) 1.00 (1.00–1.01) 0.3
Purposee
Leisure 65 (53) 119 (63) 0.7 (0.4–1.1) 0.08 23 (43) 161 63 0.5 (0.3–0.8) 0.01 8 (44) 176 (60) 0.5 (0.2–1.4) 0.2
Business/education 8 (7) 8 (4) 1.3 (0.8–2.1) 0.4 5 (9) 11 5 1.5 (0.9–2.6) 0.1 1 (6) 15 (5) 1.0 (0.4–3.0) 0.9
Humanitarian/VFR 44 (36) 52 (28) 1.5 (0.9–2.4) 0.1 22 (42) 74 29 1.8 (1.0–3.2) 0.07 8 (44) 88 (30) 1.9 (0.7–4.9) 0.2
Other characteristicsf
Type of lesion
S. aureus-positive 98 (80) 92 (49) 4.3 (2.5–7.2) <0.001 47 (88) 143 56 6.2 (2.6–15.1) <0.001 15 (83) 175 (60) 3.3 (0.9–11.8) 0.06
PVL-positive 61 (50) 56 (30) 2.4 (1.5–3.8) <0.001 46 (87) 71 27 17.2 (7.4–39.9) <0.001 14 (78) 103 (35) 6.4 (2.1–20.0) 0.001
MRSA-positive 15 (12) 8 (4) 3.2 (1.3–7.7) 0.01 13 (25) 10 4 8.0 (3.3–19.5) <0.001 14 (78) 9 (3) 110.1 (30.1–401.5) <0.001
Ulcer 38 (31) 71 (38) 0.7 (0.5–1.2) 0.2 7 (13) 102 40 0.2 (0.1–0.5) 0.001 3 (17) 106 (36) 0.3 (0.1–1.2) 0.1
Furuncle/abscess 74 (61) 107 (57) 1.2 (0.7–1.9) 0.5 43 (81) 138 54 3.7 (1.8–7.7) <0.001 13 (72) 168 (58) 1.9 (0.7–5.5) 0.2
Other 10 (8) 9 (5) 1.8 (0.7–4.5) 0.2 3 (6) 16 6 0.9 (0.3–3.2) 0.9 2 (11) 17 (6) 2.0 (0.4–9.5) 0.4
Preceding trauma
None 73 (61) 80 (44) 2.0 (1.3–3.2) 0.003 40 (75) 113 45 3.8 (1.9–7.4) <0.001 12 (67) 141 (49) 2.1 (0.8–5.6) 0.2
Insect bites 32 (27) 76 (41) 0.5 (0.3–0.9) 0.01 11 (21) 97 39 0.4 (0.2–0.8) 0.02 5 (28) 103 (36) 0.7 (0.2–2.0) 0.5
Other 15 (13) 28 (15) 0.9 (0.6–1.2) 0.5 2 (4) 41 16 0.4 (0.2–0.9) 0.03 1 (6) 42 (15) 0.6 (0.2–1.6) 0.3
Recurrent episodes 41 (34) 56 (30) 1.2 (0.7–1.9) 0.5 24 (45) 73 28 2.1 (1.1–3.8) 0.02 8 (44) 89 (30) 1.8 (0.7–4.8) 0.2
Surgical drainage 31 (25) 52 (28) 0.9 (0.5–1.5) 0.6 21 (40) 62 24 2.1 (1.1–3.8) 0.02 7 (39) 76 (26) 1.8 (0.7–4.8) 0.2
Contacts affected 21 (18) 28 (15) 1.2 (0.7–2.3) 0.5 10 (20) 39 15 1.4 (0.6–2.9) 0.4 6 (35) 43 (15) 4.1 (1.1–9.0) 0.03
Location of lesiong
Below waistline 77 (68) 129 (74) Ref. 24 (52) 182 75 Ref. 8 (53) 198 (72) Ref.
Above waistline 37 (32) 46 (26) 1.3 (0.8–2.3) 0.3 22 (48) 61 25 2.7 (1.4–5.2) 0.002 7 (47) 76 (28) 2.3 (0.8–6.5) 0.1
Data are number of subjects/bacterial isolates (column %) with given characteristic together with odds ratios (OR) and 95% conﬁdence intervals (95% CI) from univariable logistic regression. p values are testing H0: the odds of a given characteristic
are equal in the two comparison groups. p  0.05 in bold type.
Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus; PVL, Panton–Valentine leukocidin; VFR, visiting friends and relatives.
No associations were detected between any of the types of nasal carriage with prescription of antibiotics, depth of lesion, and hospitalization because of travel-associated skin and soft tissue infection (not displayed).
aMedian (inter quartile range); odds ratios per 10 years increase in age.
bRow category of cases with other destinations (Turkey, Mongolia, Afghanistan, Azerbaijan, USA) not displayed.
cFrom χ2-test.
dMedian (interquartile range); odds ratios per 14 days increase in duration of travel; information on travel duration of four subjects missing.
eRow category of one case patient with ‘other’ purpose not displayed.
fMissing data on presentation (n = 1), trauma (n = 6), contacts affected (n = 2), surgical drainage (n = 1).
gMissing data on anatomic location of lesion (n = 21).
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TABLE 5. Risk factors for antibiotic multi-resistance in imported Staphylococcus aureus
Characteristic
Multi-resistance to ‡ 2 of all tested
compoundsa
Multi-resistance to ‡ 2 non-β-lactam
antibioticsb
Multivariable
analysisc
Yes No
OR (95% CI) p
Yes No
OR (95% CI) p OR (95% CI) pn [ 54 (%) n [ 142 (%) n [ 46 (%) n [ 150 (%)
Female 24 (44) 53 (37) 1.3 (0.7–2.5) 0.4 21 (46) 56 (37) 1.4 (0.7–2.7) 0.3
Age in yearsd 33 (21–49) 30 (24–43) 1.0 (0.8–1.3)h 0.8 33.5 (21–50) 30 (24–44) 1.0 (0.8–1.3) 0.7
Travel characteristicse
Destinationf
Latin America 9 (17) 23 (16) 1.0 (0.4–2.4) 0.9 5 (11) 27 (18) 0.6 (0.2–1.5) 0.3
Africa 13 (24) 51 (36) 0.6 (0.3–1.2) 0.1 12 (26) 52 (35) 0.7 (0.3–1.4) 0.3
South Asia 17 (31) 15 (11) 3.9 (1.8–8.5) 0.001 17 (37) 15 (10) 5.3 (2.4–11.8) <0.001 3.8 (1.5–9.5) 0.004
South-East Asia 13 (24) 44 (31) 0.7 (0.3–1.4) 0.3 10 (22) 47 (31) 0.6 (0.3–1.3) 0.2
Australia/Paciﬁc 2 (4) 6 (4) 0.8 (0.2–4.5) 0.9 2 (4) 6 (4) 1.1 (0.2–5.6) 0.9
Clinical characteristicsg
Deep lesion 28 (52) 57 (40) 1.6 (0.9–3.0) 0.1 26 (57) 59 (39) 2.0 (1.0–3.9) 0.04
Systemic inﬂammationh 20 (38) 36 (26) 1.8 (09–3.4) 0.1 18 (40) 38 (26) 1.9 (1.0–3.9) 0.07
Recurrent episodes 24 (44) 46 (32) 1.7 (0.9–3.2) 0.1 20 (43) 50 (33) 1.5 (0.8–3.0) 0.2
Surgical drainage 26 (48) 40 (28) 2.4 (1.2–4.5) 0.009 23 (50) 43 (29) 2.5 (1.3–4.9) 0.008
Hospitalization due to
travel-associated SSTI
11 (20) 14 (10) 2.3 (1.0–5.4) 0.06 9 (20) 16 (11) 2.0 (0.8–4.9) 0.1
S. aureus characteristics
PVL-positivity 42 (78) 80 (56) 2.7 (1.3–5.6) 0.007 35 (76) 87 (58) 2.3 (1.1–4.9) 0.03
mecA-positivity 13 (24) 10 (7) 4.2 (1.7–10.3) 0.002 5 (11) 18 (12) 0.9 (0.3–2.6) 0.8
Spa-typei
t021 9 (17) 2 (1) 14.0 (2.9–67.2) 0.001 9 (20) 2 (1) 18.0 (3.7–86.9) <0.001 9.3 (1.7–50.0) 0.009
t008 8 (15) 4 (3) 6.0 (1.7–20.9) 0.005 3 (7) 9 (6) 1.1 (0.3–4.2) 0.9
t355 5 (9) 5 (4) 2.8 (0.8–10.1) 0.1 5 (11) 5 (3) 3.5 (1.0–12.8) 0.05 5.7 (1.5–21.2) 0.01
Data are n (column %) of subjects/bacterial isolates with given characteristic together with odds ratios (OR) and 95% conﬁdence intervals (95% CI). p-values are testing H0: the odds
of a given characteristic are equal in the two comparison groups.
Abbreviations: mecA, gene conferring methicillin resistance in S. aureus; PVL, Panton–Valentine leukocidin; SSTI, skin and soft tissue infection.
aNamely, resistance to two or more of trimethoprim-sulfamethoxazole, tetracycline, ciproﬂoxacin, clindamycin, gentamicin, rifampicin, erythromycin, methicillin; deﬁnition reﬂecting
multi-resistance to empiric therapy of S. aureus SSTI.
bNamely, resistance to two or more of trimethoprim-sulfamethoxazole, tetracycline, ciproﬂoxacin, clindamycin, gentamicin, rifampicin, erythromycin; deﬁnition reﬂecting multi-
resistance to empiric therapy of suspected MRSA SSTI.
cResults of multivariable logistic regression modelling the independent effect of spa t355, spa t021, and travel to South Asia on multi-resistance to two or more non-β-lactam
antibiotics.
dMedian (interquartile range); odds ratios per 10 years increase in age.
eNo association detected for purpose or duration of travel.
fRow category of cases with other destinations (Turkey, Mongolia, Afghanistan, Azerbaijan, USA) not displayed.
gNo association detected for type of lesion, preceding trauma, SSTI in contacts, antibiotics prescribed.
hDeﬁned as any of fever, blood leukocytosis, or elevated serum level of C-reactive protein.
iNo associations detected for any of the other spa-types.
567.e8 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMIestimated that overall 12% of all S. aureus causing SSTI in
intercontinental travellers is MRSA and observed that SSTI in
returnees from Latin America promotes the spread of the
highly virulent USA300 community-associated MRSA lineage.
This ﬁnding is in line with reports on the expansion of
USA300 from the USA into Latin America [21,22] and from
there to Europe [23]. Besides, we provide evidence for a less
prominent import of the pandemic South-West Paciﬁc and
the emerging Bay of Bengal community-associated-MRSA
clones to Europe by travellers returning from the
Philippines and India.
We show that resistance to non-β-lactam antibiotics in im-
ported S. aureus is common, amounting to 50% of all isolates,
depending on destination and antimicrobial class tested. Be-
sides, we demonstrate that about one-quarter of S. aureus
causing SSTI abroad are multi-resistant and that travel to South
Asia independently predicts multi-resistance to non-β-lactams
in these bacteria. Taken together, these ﬁndings challenge the
unguided use of trimethoprim-sulfamethoxazole, tetracycline
derivatives and clindamycin against presumed MRSA infections
in returning travellers [7–9] and support the concept ofClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectregionally adapted treatment recommendations [24–26].
Furthermore, our observations allow the assumption of a
regionally high prevalence of resistance to non-β-lactam anti-
biotics in parts of Africa and Asia. This extrapolation is sup-
ported by our recent ﬁnding of similar resistance gene content
in S. aureus collected from native Africans and travellers
returning from that continent [27,28]. Along this line, the
presented data suggest that the use of tetracycline and
trimethoprim-sulfamethoxazole as region-speciﬁc empiric
antibiotic treatment of community-associated MRSA SSTIs in
Africa and Asia is limited considering that a substantial pro-
portion of suspected cases will ultimately be caused by MSSA
because of a lack of reliable predictors of methicillin resistance.
Hence, future recommendations on the empiric antibiotic
treatment of community-associated SSTI should incorporate
resistance data gathered in MSSA and MRSA isolates alike.
Following this rationale, we would like to challenge a recent
review that looked at antibiotic resistance patterns in com-
munity MRSA globally and concluded that trimethoprim-
sulfamethoxazole is an effective ‘region-speciﬁc empiric antibi-
otic treatment [in] Asia’ [24].ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 567.e1–567.e10
CMI Nurjadi et al. Travel and import of S. aureus 567.e9Of note, we observed that those S. aureus lineages that were
strongly associated with multi-resistance to non-β-lactam an-
tibiotics (spa t021 and t355, Table 5) were also commonly PVL-
positive (91% and 100%; Fig. S1). This is alarming since PVL+
MSSA is thought to represent the reservoir from which at least
some of the successful epidemic community-associated MRSA
clones emerged through horizontal genetic exchange [29–33].
Hence, the relative abundance of multi-resistant PVL+ MSSA
among imported staphylococci could herald the evolution of
multi-resistant MRSA lineages in the community. This is in
contrast to current practice in research, surveillance and con-
trol of multi-resistant S. aureus that largely neglects antibiotic
resistance in MSSA and tends to focus on methicillin-resistant
lineages instead. Better knowledge on the accumulation of
multi-resistance in MSSA as presented here is needed to
contain potential methicillin-sensitive precursors of multi-
resistant community-associated MRSA.
Nearly two-thirds of S. aureus causing SSTI in interconti-
nental travellers were found to be PVL+ and the lukS/lukF genes
were strong predictors of SSTI-associated morbidity. In addi-
tion to conﬁrming its known associations with recurrent and
deep-seated abscesses [6,23], we were able to demonstrate
that SSTIs caused by PVL+ S. aureus were more likely to lead to
hospitalization. According to a recent review [23], this has not
been shown in an adult population before. Taking into account
the geographic and genetic diversity of S. aureus in our study,
this ﬁnding supports the concept that PVL has indeed an effect
on disease outcome rather than being merely linked with other
virulence factors—a common shortcoming of research into
infections from geographically conﬁned populations and in
clonally related S. aureus [23].
Nasal carriage of PVL+ S. aureus proved to be a risk factor for
recurrent abscesses and was associated with SSTI lesions being
located above the waistline. These observations suggest that
PVL+ strains, compared with PVL– staphylococci, are more
likely to cause manifest skin infections when spread from the
nose to areas of the body that are within the direct reach of the
hands. This emphasizes the role of colonized human nares in
perpetuating PVL+ SSTI and supports empiric nasal decoloni-
zation therapy for secondary prevention of recurrent post-
travel SSTI. Of note, we found longer duration of travel, hu-
manitarian aid work, and visiting friends and relatives to be risk
factors for nasal carriage of PVL+ S. aureus. This knowledge may
prove useful when tailoring the content of pre-travel consul-
tations and targeting infection prevention measures.
In summary, the presented ﬁndings illustrate that sentinel
surveillance of S. aureus infecting travellers is an efﬁcient way of
providing information on antimicrobial resistance in as yet
understudied regions, call for the development of regionally
stratiﬁed guidance on the antibiotic management of severeClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infimported S. aureus disease, and put the infected and colonized
traveller at the centre of interventions against the global spread
of multi-resistant S. aureus. Our network will continue this
surveillance with the aim of detecting newly emerging clones
and monitoring trends of antimicrobial resistance in imported
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